Rugo HS, Lerebours F, Ciruelos E, Drullinsky P, et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced
breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2,
multicentre, open-label, non-comparative study. Lancet Oncol 2021;22:489-498.
PMID: 33794206